Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America

  • Carina Cesar
  • , Bryan E. Shepherd
  • , Alejandro J. Krolewiecki
  • , Valeria I. Fink
  • , Mauro Schechter
  • , Suely H. Tuboi
  • , Marcelo Wolff
  • , Jean W. Pape
  • , Paul Leger
  • , Denis Padgett
  • , Juan Sierra Madero
  • , Eduardo Gotuzzo
  • , Omar Sued
  • , Catherine C. Mcgowan
  • , Daniel R. Masys
  • , Pedro E. Cahn
  • Fundación Huesped
  • Vanderbilt University School of Medicine
  • Universidade Federal do Rio de Janeiro
  • Fundación Arriaran–Facultad de Medicina Universidad de Chile
  • Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunistes
  • Universidad Autónoma de Honduras
  • Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

47 Citas (Scopus)

Resumen

Background: HAART rollout in Latin America and the Caribbean has increased from approximately 210,000 in 2003 to 390,000 patients in 2007, covering 62% (51%-70%) of eligible patients, with considerable variation among countries. No multi-cohort study has examined rates of and reasons for change of initial HAART in this region. Methodology: Antiretroviral-naïve patients≥= 18 years who started HAART between 1996 and 2007 and had at least one follow-up visit from sites in Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru were included. Time from HAART initiation to change (stopping or switching any antiretrovirals) was estimated using Kaplan-Meier techniques. Cox proportional hazards modeled the associations between change and demographics, initial regimen, baseline CD4 count, and clinical stage. Principal Findings: Of 5026 HIV-infected patients, 35% were female, median age at HAART initiation was 37 years (interquartile range [IQR], 31-44), and median CD4 count was 105 cells/uL (IQR, 38-200). Estimated probabilities of changing within 3 months and one year of HAART initiation were 16% (95% confidence interval (CI) 15-17%) and 28% (95% CI 27-29%), respectively. Efavirenz-based regimens and no clinical AIDS at HAART initiation were associated with lower risk of change (hazard ratio (HR) = 1.7 (95% CI 1.1-2.6) and 2.1 (95% CI 1.7-2.5) comparing neverapine-based regimens and other regimens to efavirenz, respectively; HR = 1.3 (95% CI 1.1-1.5) for clinical AIDS at HAART initiation). The primary reason for change among HAART initiators were adverse events (14%), death (5.7%) and failure (1.3%) with specific toxicities varying among sites. After change, most patients remained in first line regimens. Conclusions: Adverse events were the leading cause for changing initial HAART. Predictors for change due to any reason were AIDS at baseline and the use of a non-efavirenz containing regimen. Differences between participant sites were observed and require further investigation.

Idioma originalInglés
Número de artículoe10490
PublicaciónPLoS ONE
Volumen5
N.º6
DOI
EstadoPublicada - 2010

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

  1. ODS 3: Salud y bienestar
    ODS 3: Salud y bienestar

Huella

Profundice en los temas de investigación de 'Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America'. En conjunto forman una huella única.

Citar esto